Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy

Jacques E. Rossouw, Karen C. Johnson, Mary Pettinger, Mary Cushman, Per Morten Sandset, Lewis Kuller, Frits Rosendaal, Jan Rosing, Sylvia Wasserthal-Smoller, Lisa W. Martin, Joann E. Manson, Kamakshi Lakshminarayan, Jose G. Merino, John Lynch

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Background and Purpose-To test whether changes in plasma tissue factor pathway inhibitor (TFPI) levels or activated protein C resistance (normalized activated protein C resistance ratio [nAPCsr]) modify the increased risk of ischemic stroke due to postmenopausal hormone therapy. Methods-Nested case-control study of 455 cases of ischemic stroke and 565 matched control subjects in the Women's Health Initiative trials of postmenopausal hormone therapy. Results-Baseline free TFPI was associated with ischemic stroke risk (OR per SD increase, 1.17; 95% CI, 1.01-1.37; P=0.039), but baseline nAPCsr was not (OR per SD increase, 0.89; 95% CI, 0.75-1.05; P=0.15). Baseline TFPI levels and nAPCsr did not modify the effect of postmenopausal hormone therapy on ischemic stroke. Treatment-induced mean changes of-28% in free TFPI and +65% in nAPCsr did not change the risk of ischemic stroke (interaction P=0.452 and 0.971, respectively). In subgroup analyses, baseline nAPCsr was inversely associated with lacunar strokes (OR per SD increase, 0.74; 95% CI, 0.57-0.96; P=0.025) and baseline free TFPI interacted with treatment to increase large vessel atherosclerotic strokes (P=0.008). Conclusions-Procoagulant changes in TFPI or nAPCsr do not modify the increased ischemic stroke risk due to postmenopausal hormone therapy. Clinical Trial Registration-URL: www.clinicaltrials.gov. Unique identifier: NCT 00000611.

Original languageEnglish (US)
Pages (from-to)952-957
Number of pages6
JournalStroke
Volume43
Issue number4
DOIs
StatePublished - Apr 2012

Keywords

  • cerebrovascular accident
  • estrogen
  • hemostasis
  • menopause
  • randomized controlled trials

Fingerprint Dive into the research topics of 'Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy'. Together they form a unique fingerprint.

  • Cite this

    Rossouw, J. E., Johnson, K. C., Pettinger, M., Cushman, M., Sandset, P. M., Kuller, L., Rosendaal, F., Rosing, J., Wasserthal-Smoller, S., Martin, L. W., Manson, J. E., Lakshminarayan, K., Merino, J. G., & Lynch, J. (2012). Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy. Stroke, 43(4), 952-957. https://doi.org/10.1161/STROKEAHA.111.643072